The Chemotherapy Induced Oral Mucositis drugs in development market research report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chemotherapy Induced Oral Mucositis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chemotherapy Induced Oral Mucositis and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Chemotherapy Induced Oral Mucositis by 11 companies/universities/institutes. The top development phase for Chemotherapy Induced Oral Mucositis is phase ii with seven drugs in that stage. The Chemotherapy Induced Oral Mucositis pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Chemotherapy Induced Oral Mucositis pipeline products market are: Maruho, Astellas Pharma and Tosk.
The key targets in the Chemotherapy Induced Oral Mucositis pipeline products market include Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1), Histone Deacetylase (HDAC or EC 3.5.1.98), and Bacterial Cell Membrane.
The key mechanisms of action in the Chemotherapy Induced Oral Mucositis pipeline product include Histone Deacetylase (HDAC or EC 3.5.1.98) Inhibitor with one drug in Phase II. The Chemotherapy Induced Oral Mucositis pipeline products include seven routes of administration with the top ROA being Oral and two key molecule types in the Chemotherapy Induced Oral Mucositis pipeline products market including Small Molecule, and Recombinant Protein.
Chemotherapy Induced Oral Mucositis overview
Oral mucositis is an inflammation of oral mucosa most commonly occurs after chemotherapy. It is an adverse effect associated with chemotherapy and most found in patients on chemo regimen. Cytotoxic damage to the submucosal cells causes mucositis. It occurs generally after 1 week of chemo and 2 weeks after radiation therapy. It can spread from mouth to anu affecting the whole GI tract and at increased risk of developing infections. Dry mouth, sore throat, mouth ulcers, oral thrush are common symptoms. Infection if spreads to GI tract diarrhea, vomiting, abdominal cramps are seen. Uncomplicated cases requires supportive therapy while in other cases topical anesthetics to relieve pain, normal saline, salt based mouth washes to keep hygienic.
For a complete picture of Chemotherapy Induced Oral Mucositis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
